Login / Register Order My Items
mob-logo
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

RNA-Specific Terminal Caps & End-State Modifications

Custom RNA caps and terminal end states for therapeutic mRNA, vaccines, CRISPR guides, innate-immunity studies, RNA ligation, and stability workflows.

Cap 0 / Cap 1 / Cap 2 5′ ppp / pp / p NAD Cap 3′ RNA Caps ISO 9001:2015 / ISO 13485:2016 45+ Years of Expertise U.S. Facilities - Texas
Browse RNA Cap Categories Request a Quote
Talk to a chemist Request a quote
Overview Selection Guide mRNA Caps 5′ Phosphate States NAD Caps 3′ RNA Caps Design & QC Contact
Overview

RNA End Chemistry for Translation, Stability & Immune Control

RNA-specific terminal caps modify the 5′ or 3′ ends of RNA molecules to control translation efficiency, exonuclease resistance, innate immune recognition, ligation compatibility, and RNA stability. These end states are important for therapeutic mRNA, vaccines, sgRNA, small RNA cloning, RNA turnover studies, and synthetic biology workflows.

Bio-Synthesis supports a broad range of RNA terminal cap options including Cap 0, Cap 1, Cap 2, ARCA, CleanCap™, 5′ triphosphate, 5′ diphosphate, 5′ monophosphate, NAD caps, 2′,3′ cyclic phosphate, 3′ phosphate, 3′ amino, and 3′ biotin. If the RNA cap or terminal state you need is not listed, our scientific team can evaluate custom synthesis, enzymatic conversion, capping, or post-synthetic modification workflows.

Our team can help select the appropriate cap strategy based on translation goals, innate-sensing requirements, ligation chemistry, RNA length, IVT workflow, purification needs, and QC documentation requirements.

Bio-Synthesis, headquartered in Lewisville, Texas, has supported custom oligonucleotide synthesis, RNA manufacturing, and nucleic acid chemistry programs since 1984, providing research, diagnostic, and therapeutic development support through ISO 9001 and ISO 13485-aligned workflows.

mRNA Cap 0 / 1 / 2

5′ ppp / pp / p

NAD Caps

3′ RNA End States

Capping Strategy

QC Support

RNA Cap Selection Guide

Browse RNA Terminal Caps by Workflow

Use this simplified guide instead of a crowded navigation menu. Start with your RNA workflow, then jump directly to the relevant cap or end-state category.

Ⓜ

Build Translation-Ready mRNA

Use Cap 0, Cap 1, Cap 2, ARCA, or CleanCap™ for IVT mRNA, vaccines, and LNP programs.

View mRNA Caps →

P

Control 5′ Phosphate State

Use 5′ ppp, pp, or p states for immune stimulation, cloning, turnover, and enzymology workflows.

View 5′ States →

N

Study Non-Canonical Caps

Use NAD-capped RNA for bacterial regulation, synthetic biology, and cap-dependent stability studies.

View NAD Caps →

3′

Define 3′ RNA End State

Use cyclic phosphate, 3′ phosphate, amino, or biotin caps for ligation, blocking, capture, and stability.

View 3′ RNA Caps →

⚙

Plan Capping Strategy

Match cap chemistry to translation, innate sensing, ligation, poly(A), UTR, and purification requirements.

View Strategy →

✓

Confirm Quality & Release

Plan capping efficiency testing, dsRNA evaluation, HPLC, LC-MS, endotoxin, and release documentation.

View QC Support →

mRNA Caps

mRNA Caps for Translation & Stability

Canonical eukaryotic-style caps support translation initiation, 5′ protection, and reduced innate sensing. Cap 1 is commonly selected for therapeutic mRNA programs, while Cap 2 may be evaluated for additional immune-silencing needs.

Product / Modification Function Applications Code
Cap 0 (m⁷GpppN) 5′–5′ m⁷G triphosphate cap; supports translation initiation and base protection. In vitro translation, basic mRNA research. [Cap0]
Cap 1 (m⁷GpppNm) Cap 0 plus 2′-O-methylation at the first nucleotide; reduces innate sensing. Therapeutic mRNA, vaccines, LNP programs. [Cap1]
Cap 2 (m⁷GpppNmN) Cap 1 plus 2′-O-methylation at the second nucleotide; may further reduce innate sensing. Advanced therapeutic mRNA, immune-sensitive designs. [Cap2]
ARCA Anti-reverse cap analog that prevents reverse incorporation and improves cap orientation. Co-transcriptional capping for IVT mRNA. [ARCA]
CleanCap™ Series Co-transcriptional capping reagents with high capping efficiency for Cap 1/2 workflows. GMP-aligned IVT mRNA manufacturing and high-yield capping. [CleanCap]
Technical notes for mRNA caps
  • Default to Cap 1 for most in vivo mRNA delivery workflows; evaluate Cap 2 in immune-sensitive models.
  • Poly(A) length, UTRs, base chemistry such as Ψ or 5-MeC, and dsRNA removal all influence translation and immunogenicity.
  • Recommended QC may include capping efficiency, LC-MS or enzymatic assays, HPLC, and dsRNA impurity evaluation.
5′ Phosphate States

5′ Terminal Phosphate States

Uncapped or processed 5′ RNA ends are useful for innate-immunity probes, enzymology, cloning, and RNA turnover workflows.

Product / Modification Function Applications Code
5′-Triphosphate (pppN) Strong RIG-I agonist; provides modest protection against exonucleases. Immune stimulation, vaccine adjuvant studies, innate sensing research. [5′-ppp]
5′-Diphosphate (ppN) Decapping intermediate; can be immune-stimulatory. Innate sensing research and RNA processing studies. [5′-pp]
5′-Monophosphate (pN) Processed RNA end state; ligation-ready for many enzymatic workflows. Small RNA cloning, turnover studies, library preparation. [5′-p]
Technical notes for 5′ phosphate states
  • Avoid 5′-ppp in therapeutic RNA products unless immunostimulation is intended.
  • RppH, phosphatase, kinase, and enzymatic capping workflows can convert 5′ ends between ppp, pp, p, OH, and capped states.
  • Choose the 5′ state based on ligation enzyme, innate-sensing goal, and downstream purification requirements.
Non-Canonical 5′ Caps

NAD and Non-Canonical RNA Caps

Non-canonical metabolite caps such as NAD occur in bacterial or archaeal systems and can be useful in RNA regulation, synthetic biology, and stability studies.

Product / Modification Function Applications Code
5′-NAD Cap Nicotinamide adenine dinucleotide covalently linked to the 5′ end. Prokaryotic RNA regulation, synthetic circuits, innate-sensing studies. [NAD-Cap]
Technical notes for NAD-capped RNA
  • NAD capping can alter degradation pathways and RNA recognition.
  • Evaluate compatibility with ligases, cap-binding proteins, decapping enzymes, and analytical methods before workflow design.
3′ RNA Caps

3′ RNA Caps for Ligation, Blocking & Capture

3′ RNA end states can block extension, support controlled ligation, enable affinity capture, or provide reactive handles for conjugation and surface coupling.

Product / Modification Function Applications Code
2′,3′-Cyclic Phosphate Blocks extension; can form during RNase-mediated cleavage. RtcB ligation workflows, degradation mapping, RNA end-state studies. [2′3′-cPO₄]
3′-Phosphate Prevents polymerase extension; convertible to 3′-OH. Blocking, controlled ligation, cloning preparation. [3′-PO₄]
3′-Amino Provides reactive handle and blocks natural extension. Conjugation, surface coupling, probe construction. [3′-NH₂]
3′-Biotin Affinity capture and detection tag; also acts as terminal block. Pull-downs, ELISA/ISH, library selections. [Bio-3′]
Technical notes for 3′ RNA caps
  • 2′,3′-cyclic phosphate can be compatible with RtcB-type ligation; standard ligase workflows may require conversion to 3′-OH.
  • 3′ phosphate and 3′ amino can stop polymerase extension and reduce 3′ exonuclease activity in many systems.
  • 3′ biotin supports affinity capture but may require spacer optimization to reduce steric effects.
Design & Strategy

RNA Capping Strategy & Workflow Planning

Ⓜ

Therapeutic mRNA

  • Start with Cap 1 for in vivo mRNA workflows.
  • Evaluate Cap 2 when additional innate-sensing reduction is needed.
  • Coordinate cap choice with UTRs, poly(A), modified bases, and purification.
R

Innate-Immunity Studies

  • Use 5′-ppp RNA intentionally for RIG-I activation studies.
  • Use capped or converted ends when low immunogenicity is required.
  • Confirm end-state identity with suitable analytical methods.
3′

Ligation & Library Prep

  • Match 3′ end state to ligase requirements.
  • Convert 2′,3′-cPO₄ or 3′-PO₄ to 3′-OH when needed.
  • Plan purification after enzymatic conversion or ligation workflows.
Chemistry & QC

Capping Chemistry, Purification & QC Documentation

⚙

Capping & End-State Control

  • Co-transcriptional capping with ARCA or CleanCap™-style strategies.
  • Enzymatic or post-transcriptional conversion for specific 5′ and 3′ end states.
  • Workflow planning for IVT RNA, sgRNA, small RNA, and synthetic RNA constructs.
PUR

Purification Support

  • HPLC, RNase-free cleanup, desalting, and formulation options by project scope.
  • dsRNA impurity reduction planning for IVT and mRNA workflows.
  • Support for capped, tailed, modified, and conjugated RNA constructs.
QC

QC & Release

  • Capping efficiency assessment by LC-MS, enzymatic methods, or compatible assays.
  • HPLC purity, identity confirmation, dsRNA testing, endotoxin, and CoA support.
  • ISO-aligned documentation available depending on program requirements.
Quality alignment: Bio-Synthesis supports ISO 9001 / ISO 13485-aligned workflows and GLP/GMP-like practices as scoped.

Frequently Asked Questions

FAQ

Do 3′ RNA caps affect ligation?
Yes. 2′,3′-cyclic phosphate is compatible with RtcB-type ligation, while many standard T4 ligase workflows require a 3′ hydroxyl end.
Can I intentionally keep a 5′-triphosphate RNA end?
Yes, when RIG-I activation is the goal. For therapeutic RNA workflows, 5′-ppp is generally removed, converted, or capped to reduce immunogenicity and improve stability.
Cap 1 vs Cap 2 — when should I choose each?
Cap 1 is commonly used for therapeutic mRNA workflows. Cap 2 may be tested when innate sensing remains elevated or when additional 2′-O-methylation is useful in specific cell types.
What QC is recommended for capped RNA?
 Recommended QC may include capping efficiency, identity confirmation, HPLC purity, dsRNA impurity testing, endotoxin, concentration, and release documentation based on application.
Can Bio-Synthesis support custom RNA end-state requests?
 Yes. Bio-Synthesis can evaluate custom capping, enzymatic conversion, terminal modification, and analytical workflows depending on RNA length, sequence, chemistry, and intended use.
What should I provide for a quote?
 Include RNA type, sequence or length, desired 5′ and 3′ end states, cap type, scale, purification target, QC requirements, delivery format, and intended application.
More FAQ'sAll FAQ's
Contact & Quote Request

Need help selecting the right RNA cap or end state?

For the fastest review, share your RNA type, sequence or length, desired 5′ and 3′ end states, cap strategy, scale, purification target, QC requirements, delivery format, and intended application. Our scientific team can recommend the most suitable RNA capping workflow and provide a detailed quote.
Request a Quote Speak to a Scientist
Need help before quoting?
Email: info@biosyn.com
Phone: 800-227-0627 (US/CAN)
Phone: +001-972-420-8505 (INT)

Related Services

Explore supporting services for RNA synthesis, terminal caps, LNP formulation, and analytical QC.

Custom RNA Terminal Caps mRNA Transcription Therapeutic Oligos

Quote Preparation Checklist

Include RNA type, sequence/length, cap type, 5′/3′ end states, scale, purification target, QC needs, and timeline.

RNA Type Cap Type End State Scale QC Needs

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links